Study.Year | (Lu et al., 2018) [32] | (Kanellos et al., 2017) [43] | (Taghizadeh et al., 2016) [42] | (Saldanha et al., 2016) [36] | (Torres et al., 2015) [118] | (Macedo et al., 2015) [45] | (Zunino et al., 2014) [38] | (Evans et al., 2014) [1] | (Amoutzopoulos et al., 2013) [40] | (Noguer et al., 2012) [117] | (Pourghassem-Gargari et al., 2011) [44] | (Mellen et al., 2010) [119] | (Estruch et al., 2011) [115] | (Lafay et al., 2009) [116] | (Hollis et al., 2009) [37] | (Rankin et al., 2008) [39] | (Avellone et al., 2006) [114] | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Product of Intervention group | OPCs | Raisin | GSE | Resveratrol | Red wine | Resveratrol | Grape Powder | WGE | grape-based beverage (hardaliye) | LPD + dealcoholized wine | GSE | GSE | Red wine | Grape extract | Concord grape juice | Raisin | Red wine | |
Country | Taiwan | Greece | Iran | Brazil | Spain | Brazil | USA | Canada | Turkey | Spain | Iran | USA | Spain | France | USA | USA | Italy | |
Study design | Parallel | Parallel | Parallel | Cross-over | Cross-over | Parallel | Cross-over | Cross-over | Parallel | Cross-over | Parallel | Cross-over | Cross-over | Cross-over | Parallel | Cross-over | Cross-over | |
Sample Size (I/C) | 13/14 | 22/14 | 20/20 | 9/11 | 16/16 | 30/30 | 24/24 | 13/12 | 39/17 | 8/8 | 26/22 | 50/50 | 20/20 | 20/20 | 25/26 | 17/17 | 24/24 | |
Health status of participants | COPD patient | Healthy smokers | Healthy subjects | CKD patient | Healthy subjects | Healthy subjects | Healthy obese | prehypertensive, overweight | Healthy subjects | Healthy subjects | T2D | CAD or ≥ 1 cardiac risk factor | Healthy subjects | Healthy subjects | Healthy subjects | Over weight | Healthy subjects | |
Age of participantsb, y (I/C) | 71 ± 7.2 / 71 ± 7.4 | 30.8 ± 7.5/29.8 ± 5.23 | 19.8 ± 5 /21.6 ± 7 | 63.0 ± 7.5/62.0 ± 8.4 | Total: 25.5 | 21.46 ± 9.68 /22.3 ± 9.73 | Men: 37.1 ± 10.5 Women: 34.7 ± 13.9 | 46.1 ± 11.1 /38.0 ± 12.3 | 37.44 ± 8.33 /34.18 ± 5.96 | Total: 28 ± 5.3 | Total: 47.5 | Total: 52.1 ± 8.1 | Total: 37.6 ± 7.4 | Total: 21.6 ± 8.9 | 22.0 ± 4.0/26.0 ± 9.0 | Total: 26.5 ± 7.6 | Total: 43 ± 10.6 | |
BMI of participantsb, Kg/m2 (I/C) | NR | 24.4 ± 2.81/24.4 ± 2.99 | 21.6 ± 3.6/21.2 ± 1.5 | 26.8 ± 5.6/28.6 ± 4.4 | NR | NR | Men: 36.6 ± 4.4 Women: 36.9 ± 5.3 | Total:29.95 | 24.81 ± 3.29/24.97 ± 3.04 | NR | 31.0 ± 6.0/30.0 ± 4.0 | Total: 29.8 ± 6.0 | NR | Total: 23.9 ± 2.4 | 27.0 ± 1.6 /27.0 ± 1.5 | Total: 33.5 ± 6.7 | Total: 23 ± 2.5 | |
Sex of participants | M | NR | 27 | 0 | 9 | 8 | 60 | 8 | 12 | 34 | NR | NR | 25 | 40 | 20 | NR | 8 | 28 |
F | NR | 9 | 40 | 11 | 8 | 0 | 16 | 14 | 22 | NR | NR | 25 | 0 | 0 | NR | 9 | 20 | |
Product of Control group | Placebo | No raisin | Placebo | Placebo | Water with sugar | Placebo | Placeb Powder | Placebo | No hardaliye | LPD | Placebo | Placebo | Gin | Placebo | Polyphenol free grape flavored drink | Placebo | Usual wine | |
Dose of grape product, g/d | 0.15 | 90 | 0.6 | 0.5 | 160 | 0.1 | 92 | 0.35 | 500 | 300 | 0.2 | 1.3 | 320 | 0.4 | 480 | 90 | 250 | |
Dose of GPP, mg/d | ~ 150 | 178.75 | ~ 600 | ~ 500 | 361.6 | ~ 100 | 62.24 | ~ 350 | 1066 | ~ 780 | ~ 200 | ~ 1300 | ~ 832 | ~ 400 | ~ 945.5 | ~ 178.75 | ~ 650 | |
Period, wk | 8 | 4 | 8 | 16 | 8 | 12 | 9 | 6 | 6 | 2 | 8 | 14 | 12 | 10 | 12 | 8 | 12 | |
SODb, U/mgHb | I | 0.0061 ± 0.003 | NR | NR | 0.0037 ± 0.002 | NR | 0.005 ± 0.002 | NR | 0.004 ± 0.0007 | NR | 0.04 ± 0.01 | 0.001 ± 0.0002 | NR | 0.001 ± 0.0002 | 0.0025 ± 0.0004 | NR | NR | NR |
C | 0.0068 ± 0.003 | NR | NR | 0.0039 ± 0.002 | NR | 0.006 ± 0.003 | NR | 0.005 ± 0.002 | NR | 0.05 ± 0.01 | 0.001 ± 0.0001 | NR | 0.001 ± 0.0001 | 0.0023 ± 0.0003 | NR | NR | NR | |
TACb, mmol/L | I | NR | NR | 811.4 ± 122.9 | NR | 19.3 ± 2.4 | NR | NR | 1.7 ± 1.14 | 0.23 ± 0.07 | NR | NR | 0.6 ± 0.07 | NR | NR | NR | NR | 0.9 ± 0.02 |
C | NR | NR | 826.5 ± 128.9 | NR | 17.7 ± 1.5 | NR | NR | 1.2 ± 0.8 | 0.25 ± 0.1 | NR | NR | 0.6 ± 0.07 | NR | NR | NR | NR | 1 ± 0.02 | |
ORACb, μmol/L | I | NR | NR | NR | NR | NR | NR | 1536.14 ± 164.44 | NR | NR | 2586 ± 473 | NR | NR | NR | 13,885 ± 1609.2 | 2093 ± 827 | 7163 ± 1513 | NR |
C | NR | NR | NR | NR | NR | NR | 1536.14 ± 164.44 | NR | NR | 2657 ± 406 | NR | NR | NR | 14,488 ± 1698.6 | 2555 ± 936 | 8335.7 ± 1760.6 | NR | |
MDAb, μmol/L | I | 7.1 ± 1.3 | 4.3 ± 1.4 | 4.7 ± 2.1 | NR | NR | NR | NR | NR | 1.5 ± 0.3 | NR | 3.5 ± 0.6 | 0.5 ± 0.2 | 0.041 ± 0.012 | NR | NR | NR | NR |
C | 7.9 ± 1.5 | 5.1 ± 2.2 | 3.9 ± 1.1 | NR | NR | NR | NR | NR | 1.6 ± 0.4 | NR | 3.5 ± 0.7 | 0.5 ± 0.2 | 0.049 ± 0.017 | NR | NR | NR | NR | |
GPXb, U/mgHb | I | NR | NR | NR | 0.0008 ± 0.0003 | NR | 0.097 ± 0.037 | NR | NR | NR | NR | 0.029 ± 0.003 | NR | 0.0023 ± 0.0005 | 0.018 ± 0.004 | NR | NR | NR |
C | NR | NR | NR | 0.0007 ± 0.0003 | NR | 0.123 ± 0.036 | NR | NR | NR | NR | 0.022 ± 0.002 | NR | 0.0022 ± 0.0006 | 0.017 ± 0.004 | NR | NR | NR |